These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35822245)

  • 1. Process validation and
    Xun M; Guo H; Cui Q; Zhang G; Feng Z; Gui L; Zhai L
    Drug Dev Ind Pharm; 2022 Apr; 48(4):140-145. PubMed ID: 35822245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, development, and characterization of amorphous rosuvastatin calcium tablets.
    González R; Peña MÁ; Torres NS; Torrado G
    PLoS One; 2022; 17(3):e0265263. PubMed ID: 35312730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of quality attributes (mechanical strength, disintegration behavior and drug release) of tablets on the basis of characteristics of granules prepared by high shear wet granulation.
    Khan A
    PLoS One; 2021; 16(12):e0261051. PubMed ID: 34882723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation and evaluation of dried yeast tablets using different techniques.
    Al-Mohizea AM; Ahmed MO; Al-jenoobi FI; Mahrous GM; Abdel-Rahman AA
    Eur J Pharm Biopharm; 2007 Aug; 67(1):253-9. PubMed ID: 17270410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the performance of wet granulation and tablet hardness affect the drug dissolution profile of carvedilol in matrix tablets?
    Košir D; Ojsteršek T; Vrečer F
    Drug Dev Ind Pharm; 2018 Sep; 44(9):1543-1550. PubMed ID: 29848075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-destructive Determination of Disintegration Time and Dissolution in Immediate Release Tablets by Terahertz Transmission Measurements.
    Markl D; Sauerwein J; Goodwin DJ; van den Ban S; Zeitler JA
    Pharm Res; 2017 May; 34(5):1012-1022. PubMed ID: 28155076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A quality-by-design study for an immediate-release tablet platform: examining the relative impact of active pharmaceutical ingredient properties, processing methods, and excipient variability on drug product quality attributes.
    Kushner J; Langdon BA; Hicks I; Song D; Li F; Kathiria L; Kane A; Ranade G; Agarwal K
    J Pharm Sci; 2014 Feb; 103(2):527-38. PubMed ID: 24375069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combined effect of wet granulation process parameters and dried granule moisture content on tablet quality attributes.
    Gabbott IP; Al Husban F; Reynolds GK
    Eur J Pharm Biopharm; 2016 Sep; 106():70-8. PubMed ID: 27016211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing tablet disintegration characteristics of a highly water-soluble high-drug-loading formulation by granulation process.
    Pandey P; Levins C; Pafiakis S; Zacour B; Bindra DS; Trinh J; Buckley D; Gour S; Sharif S; Stamato H
    Pharm Dev Technol; 2018 Jul; 23(6):587-595. PubMed ID: 27879156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-processed excipients for direct compression of tablets.
    Franc A; Vetchý D; Vodáčková P; Kubaľák R; Jendryková L; Goněc R
    Ceska Slov Farm; 2018 Dec; 67(5-6):175-181. PubMed ID: 30871322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation development and in vitro characterization of triple layer tablet containing amlodipine besylate, rosuvastatin calcium and hydrochlorothiazide.
    Shah PA; Zaidi HA; Syed HK; Ishfaq H; Altaf RM; Pervaiz A; Khan SU; Iqbal MS; Khan J
    Pak J Pharm Sci; 2021 Mar; 34(2(Supplementary)):699-710. PubMed ID: 34275805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of In Vitro-In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls.
    Kesisoglou F; Hermans A; Neu C; Yee KL; Palcza J; Miller J
    J Pharm Sci; 2015 Sep; 104(9):2913-22. PubMed ID: 25611455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of manufacturing process variables on in vitro dissolution characteristics of extended-release tablets formulated with hydroxypropyl methylcellulose.
    Huang Y; Khanvilkar KH; Moore AD; Hilliard-Lott M
    Drug Dev Ind Pharm; 2003 Jan; 29(1):79-88. PubMed ID: 12602495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Directly compressible formulation of immediate release rosuvastatin calcium tablets stabilized with tribasic calcium phosphate.
    Zakowiecki D; Hess T; Cal K; Mikolaszek B; Garbacz G; Haznar-Garbacz D
    Pharm Dev Technol; 2022 Apr; 27(4):425-434. PubMed ID: 35499305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the performance-controlling tablet disintegration mechanisms for direct compression formulations.
    Maclean N; Walsh E; Soundaranathan M; Khadra I; Mann J; Williams H; Markl D
    Int J Pharm; 2021 Apr; 599():120221. PubMed ID: 33540006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of low dose micro-tablets by high shear wet granulation process.
    Gupta S; Thool P; Meruva S; Li J; Patel J; Agrawal A; Karki S; Bowen W; Mitra B
    Int J Pharm; 2020 Sep; 587():119571. PubMed ID: 32652180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Directly compressed rosuvastatin calcium tablets that offer hydrotropic and micellar solubilization for improved dissolution rate and extent of drug release.
    Butt S; Hasan SMF; Hassan MM; Alkharfy KM; Neau SH
    Saudi Pharm J; 2019 Jul; 27(5):619-628. PubMed ID: 31297015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of various excipients on tizanidine hydrochloride tablets prepared by direct compression.
    Khan LG; Razvi N; Anjum F; Siddiqui SA; Ghayas S
    Pak J Pharm Sci; 2014 Sep; 27(5):1249-54. PubMed ID: 25176379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of two dextrose-based directly compressible excipients.
    Olmo IG; Ghaly ES
    Drug Dev Ind Pharm; 1998 Aug; 24(8):771-8. PubMed ID: 9876525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from batch to continuous granulation: A case study of metoprolol succinate ER tablets.
    Kotamarthy L; Feng X; Alayoubi A; Kumar Bolla P; Ramachandran R; Ashraf M; O'Connor T; Zidan A
    Int J Pharm; 2022 Apr; 617():121598. PubMed ID: 35202728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.